Raymond James & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Raymond James & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,342	Closed	-$849K	–	4013
2023 Q3	$849K	Sell	7,342 -5,974	-45%	-$642K	﹤0.01%	2569
2023 Q2	$1.37M	Sell	13,316 -123,688	-90%	-$13M	﹤0.01%	2304
2023 Q1	$15M	Sell	137,004 -74,095	-35%	-$8.19M	0.01%	820
2022 Q4	$24M	Sell	211,099 -18,679	-8%	-$1.55M	0.02%	591
2022 Q3	$14.2M	Sell	229,778 -80,109	-26%	-$5.6M	0.01%	768
2022 Q2	$24.7M	Buy	309,887 +54,811	+21%	+$5.19M	0.02%	541
2022 Q1	$26.8M	Buy	255,076 +44,506	+21%	+$4.34M	0.02%	571
2021 Q4	$22.7M	Buy	210,570 +45,314	+27%	+$4.94M	0.02%	685
2021 Q3	$18.1M	Buy	165,256 +16,820	+11%	+$1.75M	0.02%	764
2021 Q2	$13.9M	Buy	148,436 +4,863	+3%	+$448K	0.01%	897
2021 Q1	$13.2M	Buy	143,573 +34,204	+31%	+$2.89M	0.01%	880
2020 Q4	$8M	Buy	109,369 +31,834	+41%	+$2.37M	0.01%	1077
2020 Q3	$6.02M	Buy	77,535 +42,671	+122%	+$2.94M	0.01%	1122
2020 Q2	$1.94M	Sell	34,864 -16,607	-32%	-$710K	﹤0.01%	1749
2020 Q1	$1.52M	Sell	51,471 -13,185	-20%	-$446K	﹤0.01%	1729
2019 Q4	$2.34M	Sell	64,656 -921	-1%	-$28.2K	﹤0.01%	1734
2019 Q3	$1.79M	Sell	65,577 -1,579	-2%	-$40.8K	﹤0.01%	1843
2019 Q2	$1.62M	Sell	67,156 -1,041	-2%	-$26.4K	﹤0.01%	1921
2019 Q1	$1.8M	Sell	68,197 -123,256	-64%	-$2.92M	﹤0.01%	1825
2018 Q4	$3.74M	Sell	191,453 -15,936	-8%	-$312K	0.01%	1244
2018 Q3	$4.06M	Buy	207,389 +19,924	+11%	+$379K	0.01%	1345
2018 Q2	$3.1M	Buy	187,465 +20,621	+12%	+$314K	0.01%	1478
2018 Q1	$2.37M	Sell	166,844 -13,905	-8%	-$205K	﹤0.01%	1599
2017 Q4	$2.64M	Sell	180,749 -44,531	-20%	-$625K	﹤0.01%	1517
2017 Q3	$2.86M	Sell	225,280 -26,835	-11%	-$341K	0.01%	1398
2017 Q2	$2.99M	Buy	252,115 +52,745	+26%	+$656K	0.01%	1324
2017 Q1	$2.95M	Buy	199,370 +14,188	+8%	+$230K	0.01%	1301
2016 Q4	$3M	Buy	185,182 +6,691	+4%	+$121K	0.01%	1243
2016 Q3	$3.24M	Buy	178,491 +11,610	+7%	+$227K	0.01%	1169
2016 Q2	$2.75M	Sell	166,881 -9,543	-5%	-$154K	0.01%	1149
2016 Q1	$2.92M	Sell	176,424 -81,335	-32%	-$1.42M	0.01%	1085
2015 Q4	$5.59M	Buy	257,759 +48,222	+23%	+$939K	0.02%	760
2015 Q3	$4.15M	Buy	209,537 +3,504	+2%	+$111K	0.02%	834
2015 Q2	$7.16M	Buy	206,033 +20,319	+11%	+$620K	0.03%	651
2015 Q1	$4.82M	Buy	185,714 +7,169	+4%	+$131K	0.02%	759
2014 Q4	$2.3M	Buy	+178,545	New	+$2.23M	0.01%	1079

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Raymond James & Associates's HZNP Position: Q4 2023 in Review

Raymond James & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,342 shares — an estimated $849K sold.

Raymond James & Associates first reported a position in HZNP in Q4 2014 and held it in 36 quarters. The position peaked at $26.8M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Raymond James & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Raymond James & Associates sold 7,342 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $849K.
Raymond James & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 36 quarters.
Raymond James & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $26.8M in Q1 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.